Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.43 |
| ▸ | RXRG | P48443 | 6/20 | 0.37 |
| ▸ | RXRB | P28702 | 5/20 | 0.37 |
| ▸ | RARG | P13631 | 7/20 | 0.36 |
| ▸ | RARB | P10826 | 6/20 | 0.36 |
| ▸ | RARA | P10276 | 6/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541470 | 1.00 | RXRA (0.43) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6541989 | 0.85 | RXRA (0.35) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6541992 | 0.85 | RXRA (0.35) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6542673 | 0.84 | RXRA (0.37) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6542671 | 0.84 | RXRA (0.37) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6541508 | 0.82 | HPGD (0.41) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6541500 | 0.82 | HPGD (0.41) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6542944 | 0.79 | RXRA (0.33) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6542941 | 0.79 | RXRA (0.33) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6542156 | 0.79 | RXRA (0.50) | RXRARXRGRXRBRARGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421061-A4 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INC (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1421061-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | Incyte San Diego Incorporated (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003016267-A1 | OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA | INCYTE SAN DIEGO INCORPORATED (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083357-A1 | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia | OAT, CPT1A, CYP27A1 | RXRA 793/4885RXRG 744/4885RXRB 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.